NCT02104765

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY2951742 in healthy Japanese and Caucasians. The study will also investigate how the body processes the drug and how the drug affects the body. The study is expected to last about 5 to 7 months, depending on the arm.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	LY2951742	Administered subcutaneously.
DRUG	Placebo	Administered subcutaneously.

Timeline

• Start date: 2014-06-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2014-04-04
• Last updated: 2019-06-14
• Results posted: 2019-06-14

Locations

1 site across 1 country: United States